Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes (original) (raw)

• Cohen, P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 268, 5001–5010 (2001).
  Article CAS PubMed Google Scholar
• Verkhivker, G. M. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics 23, 1919–1926 (2007).
  Article CAS PubMed Google Scholar
• Giamas, G. et al. Kinases as targets in the treatment of solid tumors. Cell. Signal. 22, 984–1002 (2010).
  Article CAS PubMed Google Scholar
• Zsila, F., Fitos, I., Bencze, G., Keri, G. & Orfi, L. Determination of human serum α1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr. Med. Chem. 16, 1964–1977 (2009).
  Article CAS PubMed Google Scholar
• Cheng, H. & Force, T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106, 21–34 (2010).
  Article CAS PubMed Google Scholar
• Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011–2019 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Perez, E. A. et al. Cardiac safety of lapatinib: pooled analysis of 3,689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679–686 (2008).
  Article PubMed Google Scholar
• Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct. Mol. Biol. 11, 1192–1197 (2004).
  Article CAS Google Scholar
• Okram, B. et al. A general strategy for creating “inactive-conformation” Abl inhibitors. Chem. Biol. 13, 779–786 (2006).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999).
  Article CAS PubMed Google Scholar
• Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28–39 (2009).
  Article CAS Google Scholar
• Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53, 1413–1437 (2010).
  Article CAS PubMed Google Scholar
• Bhargava, P. VEGF kinase inhibitors: how do they cause hypertension? Am. J. Physiol. Regul. Integr Comp. Physiol. 297, R1–R5 (2009).
  Article CAS PubMed Google Scholar
• Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Rev. Drug. Discov. 8, 627–644 (2009).
  Article CAS Google Scholar
• Matsui, T. et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104, 330–335 (2001).
  Article CAS PubMed Google Scholar
• Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotech. 25, 1035–1044 (2007). A definitive application of open-ended proteomic technology used to gain insight into off-target effects of kinase inhibitors. This approach underscores the inherent challenges in being able to identify mechanisms of toxicity.
  Article CAS Google Scholar
• Meissner, K. et al. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J. Histochem. Cytochem. 54, 215–221 (2006).
  Article CAS PubMed Google Scholar
• Kerkela, R. et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15–25 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Thirunavukkarasu, M. et al. VEGFR1 (Flt-1 +/−) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free. Radic. Biol. Med. 42, 1487–1495 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Thirunavukkarasu, M. et al. Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J. Cell. Mol. Med. 12, 1284–1302 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chintalgattu, V. et al. Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472–484 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47, 887–893 (2006).
  Article CAS PubMed Google Scholar
• Orphanos, G. S., Ioannidis, G. N. & Ardavanis, A. G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48, 964–970 (2009).
  Article CAS PubMed Google Scholar
• Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotech. 26, 127–132 (2008). The technology described in this study opened the door for broad scale assessment of competitive inhibition of kinase inhibitors, thereby immediately allowing one to understand the challenges associated with making selective kinase inhibitors.
  Article CAS Google Scholar
• Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521–531 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Shell, S. A. et al. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7, 1769–1775 (2008).
  Article CAS PubMed Google Scholar
• Rixe, O., Billemont, B. & Izzedine, H. Hypertension as a predictive factor of sunitinib activity. Ann. Oncol. 18, 1117 (2007).
  Article CAS PubMed Google Scholar
• Bono, P. et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann. Oncol. 20, 393–394 (2009).
  Article CAS PubMed Google Scholar
• Rini, B. I. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3743–3748 (2008).
  Article CAS PubMed Google Scholar
• Goodwin, R. et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann. Oncol. 21, 2220–2226 (2010).
  Article CAS PubMed Google Scholar
• Hasinoff, B. B. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244, 190–195 (2010).
  Article CAS PubMed Google Scholar
• Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotech. 23, 329–336 (2005).
  Article CAS Google Scholar
• Olaharski, A. J. et al. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput. Biol. 5, e1000446 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98–102 (2009). A revolutionary application of airborne radiation; the assessment of radioisotopes in human tissues to estimate proliferation rates. This work definitively shows that the myocardium exhibits a baseline proliferation and has ushered out the notion that the adult heart is forever postmitotic.
  Article CAS PubMed PubMed Central Google Scholar
• Padin-Iruegas, M. E. et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 120, 876–887 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• De Angelis, A. et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121, 276–292 (2010). A thorough demonstration of the use of exogenous stem cells to attenuate cardiotoxicity induced by doxorubicin. These data provide rationale for the hypothesis that the stem cell compartment in the heart is a target of toxicity. This hypothesis was put forth to explain the increased incidence of heart failure in doxorubicin-treated children.
  Article CAS PubMed Google Scholar
• Kajstura, J. et al. Cardiac stem cells and myocardial disease. J. Mol. Cell. Cardiol. 45, 505–513 (2008).
  Article CAS PubMed Google Scholar
• Huang, C. et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 121, 675–683 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lipshultz, S. E. Exposure to anthracyclines during childhood causes cardiac injury. Semin. Oncol. 33, S8–S14 (2006).
  Article CAS PubMed Google Scholar
• Li, M. et al. c-kit is required for cardiomyocyte terminal differentiation. Circ. Res. 102, 677–685 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459–465 (2002).
  Article CAS PubMed Google Scholar
• Harris, I. S. et al. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110, 718–723 (2004).
  Article CAS PubMed Google Scholar
• Lin, R. C. et al. PI3K(p110α) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler. Thromb. Vasc. Biol. 30, 724–732 (2010).
  Article CAS PubMed Google Scholar
• Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).
  Article CAS PubMed Google Scholar
• Adams, R. H. et al. Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell 6, 109–116 (2000).
  Article CAS PubMed Google Scholar
• Molkentin, J. D. & Robbins, J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J. Mol. Cell. Cardiol. 46, 130–136 (2009). A well-written review about the necessity to understand in deeper detail how transgenic and knockout mice are created, in order to effectively interpret the phenotype that is observed. Specific emphasis is placed on genetically modified mice and their role in understanding cardiac biology.
  Article CAS PubMed Google Scholar
• Braam, S. R., Passier, R. & Mummery, C. L. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol. Sci. 30, 536–545 (2009).
  Article CAS PubMed Google Scholar
• Braam, S. R. et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 107–116 (2010). One of the first articles to use stem cell-derived cardiomyocytes as a model for assessing cardio-active compounds.
  Article CAS PubMed Google Scholar
• Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D. & Will, Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539–547 (2007).
  Article CAS PubMed Google Scholar
• Kimes, B. W. & Brandt, B. L. Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 98, 367–381 (1976).
  Article CAS PubMed Google Scholar
• Merten, K. E., Jiang, Y., Feng, W. & Kang, Y. J. Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J. Pharmacol. Exp. Ther. 319, 934–940 (2006).
  Article CAS PubMed Google Scholar
• Wang, Y. J. et al. Time-dependent block of ultrarapid-delayed rectifier K+ currents by aconitine, a potent cardiotoxin, in heart-derived H9c2 myoblasts and in neonatal rat ventricular myocytes. Toxicol. Sci. 106, 454–463 (2008).
  Article CAS PubMed Google Scholar
• Will, Y. et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153–161 (2008).
  Article CAS PubMed Google Scholar
• Simpson, P., McGrath, A. & Savion, S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ. Res. 51, 787–801 (1982).
  Article CAS PubMed Google Scholar
• Simpson, P. & Savion, S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ. Res. 50, 101–116 (1982).
  Article CAS PubMed Google Scholar
• Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12, 908–916 (2006). The first paper describing the cardiotoxicity of kinase inhibitors. The results in this paper changed the approach for assessing cardiotoxicity of kinase inhibitors.
  Article CAS PubMed Google Scholar
• Hasinoff, B. B., Patel, D. & O'Hara, K. A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol. 74, 1722–1728 (2008).
  Article CAS PubMed Google Scholar
• Zhang, J. et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 104, e30–e41 (2009).
  CAS PubMed PubMed Central Google Scholar
• Itskovitz-Eldor, J. et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 6, 88–95 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Kehat, I. et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nature Biotech. 22, 1282–1289 (2004).
  Article CAS Google Scholar
• Satin, J. et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 26, 1961–1972 (2008).
  Article CAS PubMed Google Scholar
• Vidarsson, H., Hyllner, J. & Sartipy, P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev. 6, 108–120 (2010).
  Article Google Scholar
• Liang, H. et al. Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell Physiol. Biochem. 25, 459–466 (2010).
  Article CAS PubMed Google Scholar
• Hill, A. J., Teraoka, H., Heideman, W. & Peterson, R. E. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol. Sci. 86, 6–19 (2005).
  Article CAS PubMed Google Scholar
• Jopling, C. et al. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 464, 606–609 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Baker, K., Warren, K. S., Yellen, G. & Fishman, M. C. Defective “pacemaker” current (Ih) in a zebrafish mutant with a slow heart rate. Proc. Natl Acad. Sci. USA 94, 4554–4559 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Eimon, P. M. & Rubinstein, A. L. The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin. Drug. Metab. Toxicol. 5, 393–401 (2009).
  Article CAS PubMed Google Scholar
• Pugach, E. K., Li, P., White, R. & Zon, L. Retro-orbital injection in adult zebrafish. J. Vis. Exp. 34, 1645 (2009).
  Google Scholar
• Wenner, M. The most transparent research. Nature Med. 15, 1106–1109 (2009).
  Article CAS PubMed Google Scholar
• Herman, E. H. & Ferrans, V. J. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol. 16, 102–106 (1986).
  Article CAS PubMed Google Scholar
• Herman, E. H., Ferrans, V. J., Jordan, W. & Ardalan, B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 31, 85–97 (1981).
  CAS PubMed Google Scholar
• Herman, E. H. & Ferrans, V. J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin. Oncol. 25, 15–21 (1998).
  CAS PubMed Google Scholar
• Fernandez, A. et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J. Clin. Invest. 117, 4044–4054 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67 (2000).
  Article CAS PubMed Google Scholar
• Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
  Article CAS PubMed Google Scholar
• Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).
  Article CAS PubMed Google Scholar
• Eschenhagen, T. et al. Cardiovascular side-effects of cancer therapies: a position statement from the heart failure association of the european society of cardiology. Eur. J. Heart Fail 13, 1–10 (2011).
  Article PubMed Google Scholar
• Zhang, L. & Dokainish, H. Echocardiography in the assessment of heart failure. Minerva Cardioangiol. 57, 457–466 (2009).
  CAS PubMed Google Scholar
• Apple, F. S. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin. Chem. 55, 1303–1306 (2009).
  Article CAS PubMed Google Scholar
• Apple, F. High-sensitivity cardiac troponin assays: what analytical and clinical issues need to be addressed before introduction into clinical practice? Clin. Chem. 56, 886–891 (2010).
  Article CAS Google Scholar
• Polena, S. et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc. West. Pharmacol. Soc. 48, 142–144 (2005).
  CAS PubMed Google Scholar
• Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474–2481 (2006).
  Article CAS PubMed Google Scholar
• Cardinale, D. et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28, 3910–3916 (2010).
  Article CAS PubMed Google Scholar
• Henderson, I. C. et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7, 560–571 (1989).
  Article CAS PubMed Google Scholar
• Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E. & Giardina, B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem. 16, 1656–1672 (2009).
  Article CAS PubMed Google Scholar
• Lewis, G. D., Asnani, A. & Gerszten, R. E. Application of metabolomics to cardiovascular biomarker and pathway discovery. Am. Coll. Cardiol. 52, 117–123 (2008).
  Article CAS Google Scholar
• Lewis, G. D. et al. Metabolic signatures of exercise in human plasma. Sci. Transl. Med. 2, 33–37 (2010).
  Article CAS Google Scholar
• Olson, E. N. A decade of discoveries in cardiac biology. Nature Med. 10, 467–474 (2004).
  Article CAS PubMed Google Scholar
• Brini, M. & Carafoli, E. Calcium pumps in health and disease. Physiol. Rev. 89, 1341–1378 (2009).
  Article CAS PubMed Google Scholar
• Swain, J. L., Sabina, R. L., McHale, P. A., Greenfield, J. C. Jr & Holmes, E. W. Prolonged myocardial nucleotide depletion after brief ischemia in the open-chest dog. Am. J. Physiol. 242, H818–H826 (1982).
  CAS PubMed Google Scholar
• Khouri, E. M., Gregg, D. E. & Rayford, C. R. Effect of exercise on cardiac output, left coronary flow and myocardial metabolism in the unanesthetized dog. Circ. Res. 17, 427–437 (1965).
  Article CAS PubMed Google Scholar
• Barry, S. P., Davidson, S. M. & Townsend, P. A. Molecular regulation of cardiac hypertrophy. Int. J. Biochem. Cell. Biol. 40, 2023–2039 (2008).
  Article CAS PubMed Google Scholar
• Oliveira, R. S. et al. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice. J. Physiol. 587, 3899–3910 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, T. et al. CaMKIIδ isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J. Biol. Chem. 282, 35078–35087 (2007).
  Article CAS PubMed Google Scholar
• Zhang, T. et al. Phospholamban ablation rescues sarcoplasmic reticulum Ca2+ handling but exacerbates cardiac dysfunction in CaMKIIδC transgenic mice. Circ. Res. 106, 354–362 (2010).
  Article CAS PubMed Google Scholar
• Vittone, L., Mundina-Weilenmann, C. & Mattiazzi, A. Phospholamban phosphorylation by CaMKII under pathophysiological conditions. Front. Biosci. 13, 5988–6005 (2008).
  Article CAS PubMed Google Scholar
• Ghoreschi, K., Laurence, A. & O'Shea, J. J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nature Immunol. 10, 356–360 (2009).
  Article CAS Google Scholar
• Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 105, 18895–18900 (2008).
  Article PubMed PubMed Central Google Scholar
• Mariani, S. et al. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk. Res. 34, e5–e7 (2010).
  Article CAS PubMed Google Scholar
• Agostino, N. et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J. Oncol. Pharm. Pract. 4 Aug 2010 (doi:10.1177/1078155210378913).
• Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811–2821 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Klein, M. et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118, 2081–2090 (2008).
  Article CAS PubMed Google Scholar
• Ghofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171–1177 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C. H. et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ. Res. 99, 617–625 (2006).
  Article CAS PubMed Google Scholar
• Makiyama, Y. et al. Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury. Tohoku J. Exp. Med. 215, 299–306 (2008).
  Article CAS PubMed Google Scholar
• Ayach, B. B. et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc. Natl Acad. Sci. USA 103, 2304–2309 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Force, T. et al. Research priorities in hypertrophic cardiomyopathy: report of a working group of the National Heart, Lung, and Blood Institute. Circulation 122, 1130–1133 (2010).
  Article PubMed PubMed Central Google Scholar
• Ahmad, F. et al. Increased α2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 112, 3140–3148 (2005).
  Article CAS PubMed Google Scholar
• Tao, R., Zhang, J., Vessey, D. A., Honbo, N. & Karliner, J. S. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc. Res. 74, 56–63 (2007).
  Article CAS PubMed Google Scholar
• Moga, M. A., Nakamura, T. & Robbins, J. Genetic approaches for changing the heart and dissecting complex syndromes. J. Mol. Cell. Cardiol. 45, 148–155 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Aoki, Y., Niihori, T., Narumi, Y., Kure, S. & Matsubara, Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum. Mutat. 29, 992–1006 (2008).
  Article CAS PubMed Google Scholar
• Gelb, B. D. & Tartaglia, M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 15,R220–R226 (2006).
  Article CAS Google Scholar
• Yamaguchi, O. et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 114, 937–943 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• McMullen, J. R. & Jay, P. Y. PI3K(p110α) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 6, 910–913 (2007).
  Article CAS PubMed Google Scholar
• McMullen, J. R. et al. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104, 612–617 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Rose, R. A., Kabir, M. G. & Backx, P. H. Altered heart rate and sinoatrial node function in mice lacking the cAMP regulator phosphoinositide 3-kinase-γ. Circ. Res. 101, 1274–1282 (2007).
  Article CAS PubMed Google Scholar
• Oudit, G. Y. et al. Phosphoinositide 3-kinase-γ-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147–2152 (2003).
  Article CAS PubMed Google Scholar
• Oudit, G. Y. et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449–471 (2004).
  Article CAS PubMed Google Scholar
• Mora, A. et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 22, 4666–4676 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097–2104 (2006).
  Article CAS PubMed Google Scholar
• DeBosch, B., Sambandam, N., Weinheimer, C., Courtois, M. & Muslin, A. J. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J. Biol. Chem. 281, 32841–32851 (2006).
  Article CAS PubMed Google Scholar
• Lee, C. H., Inoki, K. & Guan, K. L. mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. Toxicol. 47, 443–467 (2007).
  Article CAS PubMed Google Scholar
• Ciuffreda, L., Di Sanza, C., Incani, U. C. & Milella, M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 10, 10484–10495 (2010).
  Article Google Scholar
• Blair, E. et al. Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10, 1215–1220 (2001).
  Article CAS PubMed Google Scholar
• Zhang, P. et al. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918–924 (2008).
  Article CAS PubMed Google Scholar
• Matsuda, T. et al. Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overload. Proc. Natl Acad. Sci. USA 105, 20900–20905 (2008).
  Article PubMed PubMed Central Google Scholar
• Kerkela, R. et al. Deletion of GSK-3β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Invest. 118, 3609–3618 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Woulfe, K. C. et al. Glycogen synthase kinase-3β regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ. Res. 106, 1635–1645 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Barriere, C. et al. Mice thrive without Cdk4 and Cdk2. Mol. Oncol. 1, 72–83 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Liem, D. A. et al. Cyclin-dependent kinase 2 signaling regulates myocardial ischemia/reperfusion injury. J. Mol. Cell. Cardiol. 45, 610–616 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Perez Fidalgo, J. A., Roda, D., Rosello, S., Rodriguez-Braun, E. & Cervantes, A. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clin. Transl. Oncol. 11, 787–798 (2009).
  Article CAS PubMed Google Scholar
• Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nature Rev. Drug. Discov. 8, 547–566 (2009).
  Article CAS Google Scholar
• Chopra, P., Sethi, G., Dastidar, S. G. & Ray, A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin. Investig. Drugs 19, 27–43 (2010).
  Article CAS PubMed Google Scholar
• Noma, T. et al. β-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445–2458 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• De Keulenaer, G. W., Doggen, K. & Lemmens, K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 106, 35–46 (2010).
  Article CAS PubMed Google Scholar
• Iwamoto, R. et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl Acad. Sci. USA 100, 3221–3226 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, F. F. et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am. J. Physiol. 289, H660–H666 (2005).
  CAS Google Scholar
• Garcia-Rivello, H. et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am. J. Physiol. 289, H1153–H1160 (2005).
  CAS Google Scholar
• Fazel, S. et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116, 1865–1877 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Hilfiker-Kleiner, D., Limbourg, A. & Drexler, H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovas. Med. 15, 152–157 (2005).
  Article CAS Google Scholar
• Kunisada, K. et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 97, 315–319 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Barry, S. P., Townsend, P. A., Latchman, D. S. & Stephanou, A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol. Med. 13, 82–89 (2007).
  Article CAS PubMed Google Scholar
• Peng, X. et al. Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J. Clin. Invest. 116, 217–227 (2006).
  Article CAS PubMed Google Scholar
• O'Cochlain, D. F. et al. Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy. Hum. Mol. Genet. 13, 2505–2518 (2004).
  Article CAS PubMed Google Scholar
• Honda, H. et al. Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice. Oncogene 18, 3821–3830 (1999).
  Article CAS PubMed Google Scholar
• Shi, J., Zhang, Y. W., Yang, Y., Zhang, L. & Wei, L. ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. J. Mol. Cell Cardiol. 49, 819–828 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, Y. M. et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 20, 916–925 (2006).
  Article CAS PubMed Google Scholar
• Ikeda, Y. et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J. Biol. Chem. 284, 35839–35849 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, M. et al. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum. Mol. Genet. 18, 701–713 (2009).
  Article CAS PubMed Google Scholar
• Lorenz, K., Schmitt, J. P., Schmitteckert, E. M. & Lohse, M. J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nature Med. 15, 75–83 (2009).
  Article CAS PubMed Google Scholar
• Lips, D. J. et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109, 1938–1941 (2004).
  Article CAS PubMed Google Scholar
• Kehat, I. & Molkentin, J. D. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann. NY Acad. Sci. 1188, 96–102 (2010).
  Article CAS PubMed Google Scholar
• Nakamura, T. et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J. Clin. Invest. 117, 2123–2132 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Q. et al. PKCα, but not PKCβ or PKCγ, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ. Res. 105, 194–200 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Takimoto, E. et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119, 408–420 (2009).
  CAS PubMed PubMed Central Google Scholar
• Guazzi, M., Vicenzi, M., Arena, R. & Guazzi, M. D. PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, rlacebo-controlled study. Circ. Heart Fail. 29 Oct 2010 (doi:10.1161/circheartfailure.110.944694).
• Muraski, J. A. et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nature Med. 13, 1467–1475 (2007).
  Article CAS PubMed Google Scholar
• Sag, C. M. et al. Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ. Heart Fail. 2, 664–675 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ling, H. et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230–1240 (2009).
  Article PubMed PubMed Central Google Scholar
• Lymperopoulos, A. et al. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285, 16378–16386 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Eckhart, A. D. et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ. Res. 86, 43–50 (2000).
  Article CAS PubMed Google Scholar
• Yamaguchi, O. et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc. Natl Acad. Sci. USA 100, 15883–15888 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Taniike, M. et al. Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation 117, 545–552 (2008).
  Article CAS PubMed Google Scholar
• Hescheler, J. et al. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ. Res. 69, 1476–1486 (1991).
  Article CAS PubMed Google Scholar
• Zordoky, B. N. & El-Kadi, A. O. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J. Pharmacol. Toxicol. Methods 56, 317–322 (2007).
  Article CAS PubMed Google Scholar
• Field, L. J. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice. Science 239, 1029–1033 (1988).
  Article CAS PubMed Google Scholar
• White, S. M., Constantin, P. E. & Claycomb, W. C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. 286, H823–H829 (2004).
  CAS Google Scholar
• Eimre, M. et al. Distinct organization of energy metabolism in HL-1 cardiac cell line and cardiomyocytes. Biochim. Biophys. Acta 1777, 514–524 (2008).
  Article CAS PubMed Google Scholar
• Fritzsche, M., Fredriksson, J. M., Carlsson, M. & Mandenius, C. F. A cell-based sensor system for toxicity testing using multiwavelength fluorescence spectroscopy. Anal. Biochem. 387, 271–275 (2009).
  Article CAS PubMed Google Scholar
• Zhang, Y., Nuglozeh, E., Toure, F., Schmidt, A. M. & Vunjak-Novakovic, G. Controllable expansion of primary cardiomyocytes by reversible immortalization. Hum. Gene Ther. 20, 1687–1696 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Pentassuglia, L. et al. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 313, 1588–1601 (2007).
  Article CAS PubMed Google Scholar
• Deng, X. F., Rokosh, D. G. & Simpson, P. C. Autonomous and growth factor-induced hypertrophy in cultured neonatal mouse cardiac myocytes. Comparison with rat. Circ. Res. 87, 781–788 (2000).
  Article CAS PubMed Google Scholar
• Gussak, I., Chaitman, B. R., Kopecky, S. L. & Nerbonne, J. M. Rapid ventricular repolarization in rodents: electrocardiographic manifestations, molecular mechanisms, and clinical insights. J. Electrocardiol. 33, 159–170 (2000).
  Article CAS PubMed Google Scholar
• Brouillette, J., Clark, R. B., Giles, W. R. & Fiset, C. Functional properties of K+ currents in adult mouse ventricular myocytes. J. Physiol. 559, 777–798 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Volz, A., Piper, H. M., Siegmund, B. & Schwartz, P. Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J. Mol. Cell. Cardiol. 23, 161–173 (1991).
  Article CAS PubMed Google Scholar
• Ellingsen, O. et al. Adult rat ventricular myocytes cultured in defined medium: phenotype and electromechanical function. Am. J. Physiol. 265, H747–H754 (1993).
  CAS PubMed Google Scholar
• Bistola, V. et al. Long-term primary cultures of human adult atrial cardiac myocytes: cell viability, structural properties and BNP secretion in vitro. Int. J. Cardiol. 131, 113–122 (2008).
  Article PubMed Google Scholar
• Benardeau, A. et al. Primary culture of human atrial myocytes is associated with the appearance of structural and functional characteristics of immature myocardium. J. Mol. Cell. Cardiol. 29, 1307–1320 (1997).
  Article CAS PubMed Google Scholar
• Li, R. K. et al. Human pediatric and adult ventricular cardiomyocytes in culture: assessment of phenotypic changes with passaging. Cardiovasc. Res. 32, 362–373 (1996).
  Article CAS PubMed Google Scholar
• Davidson, M. M. et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39, 133–147 (2005).
  Article CAS PubMed Google Scholar
• Zhou, J. et al. GSK-3α directly regulates β adrenergic signaling and the response of the heart to hemodynamic stress in mice. J. Clin. Invest. 120, 2280–2291 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kondo, R. P. et al. Comparison of contraction and calcium handling between right and left ventricular myocytes from adult mouse heart: a role for repolarization waveform. J. Physiol. 571, 131–46 (2006).
  Article CAS PubMed Google Scholar